Background: CYP2C9 is one of the most important phase I drug-metabolizing enzymes in liver. The objective of this work was to investigate the effects of apigenin on the metabolism of losartan and human CYP2C9 and rat CYP2C11 activity in vitro. Methods: Different concentrations of apigenin were added to a 100 mmol/l Tris-HCl reaction mixture containing 2 pmol/ml recombinant human CYP2C9.1, 0.25 mg/ml human liver microsomes or 0.5 mg/ml rat liver microsomes to determine the half maximal inhibition or a half-maximal inhibitory concentration (IC50) on the metabolism of losartan. In addition, diclofenac used as CYP2C9 substrate was performed to determine the effects of apigenin on CYP2C9. Results: The results showed that apigenin has the inhibitory effect on the metabolism of losartan in vitro, the IC50 was 7.61, 4.10 and 11.07 μmol/l on recombinant CYP2C9 microsomes, human liver microsomes and rat liver microsomes, respectively. Meanwhile, apigenin's mode of action on human CYP2C9 activity was competitive for the substrate diclofenac. In contrast to its potent inhibition of CYP2C9 in humans (9.51 μmol/l), apigenin had lesser effects on CYP2C11 in rat (IC50 = 15.51 μmol/l). Conclusion: The observations imply that apigenin has the inhibitory effect on the metabolism of losartan and CYP2C9 activity in vitro. More attention should be paid as to when losartan should be administrated combined with apigenin.

Keywords:
Metabolism, In vitro, Apigenin, Losartan, CYP2C9
1.
Yoon MS, Lee JS, Choi BM, Jeong YI, Lee CM, Park JH, Moon Y, Sung SC, Lee SK, Chang YH, Chung HY, Park YM: Apigenin inhibits immunostimulatory function of dendritic cells: implication of immunotherapeutic adjuvant. Mol Pharmacol 2006;70:1033-1044.
2.
Mafuvadze B, Cook M, Xu Z, Besch-Williford CL, Hyder SM: Effects of dietary apigenin on tumor latency, incidence and multiplicity in a medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced breast cancer model. Nutr Cancer 2013;65:1184-1191.
3.
Maggioni D, Garavello W, Rigolio R, Pignataro L, Gaini R, Nicolini G: Apigenin impairs oral squamous cell carcinoma growth in vitro inducing cell cycle arrest and apoptosis. Int J Oncol 2013;43:1675-1682.
4.
Khan TH, Jahangir T, Prasad L, Sultana S: Inhibitory effect of apigenin on benzo(a)pyrene-mediated genotoxicity in swiss albino mice. J Pharm Pharmacol 2006;58:1655-1660.
5.
Kuo CH, Weng BC, Wu CC, Yang SF, Wu DC, Wang YC: Apigenin has anti-atrophic gastritis and anti-gastric cancer progression effects in Helicobacter pylori-infected mongolian gerbils. J Ethnopharmacol 2014;151:1031-1039.
6.
Dong J, Qiu J, Wang J, Li H, Dai X, Zhang Y, Wang X, Tan W, Niu X, Deng X, Zhao S: Apigenin alleviates the symptoms of Staphylococcus aureus pneumonia by inhibiting the production of alpha‐hemolysin. FEMS Microbiol Lett 2013;338:124-131.
7.
Wang YC, Huang KM: In vitro anti-inflammatory effect of apigenin in the Helicobacter pylori-infected gastric adenocarcinoma cells. Food Chem Toxicol 2013;53:376-383.
8.
Wang Z, Sun W, Huang CK, Wang L, Xia MM, Cui X, Hu GX, Wang ZS: Inhibitory effects of curcumin on activity of cytochrome P450 2C9 enzyme in human and 2C11 in rat liver microsomes. Drug Dev Ind Pharm 2015;41:613-616.
9.
Wang X, Lee WY, Or PM, Yeung JH: Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat. Phytomedicine 2009;17:203-211.
10.
Si D, Wang Y, Zhou YH, Guo Y, Wang J, Zhou H, Li ZS, Fawcett JP: Mechanism of CYP2C9 inhibition by flavones and flavonols. Drug Metab Dispos 2009;37:629-634.
11.
Allen SW, Mueller L, Williams SN, Quattrochi LC, Raucy J: The use of a high-volume screening procedure to assess the effects of dietary flavonoids on human CYP1A1 expression. Drug Metab Dispos 2001;29:1074-1079.
12.
Gradolatto A, Canivenc-Lavier MC, Basly JP, Siess MH, Teyssier C: Metabolism of apigenin by rat liver phase I and phase II enzymes and by isolated perfused rat liver. Drug Metabo Dispos 2004;32:58-65.
13.
Ho PC, Saville DJ, Wanwimolruk S: Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 2001;4:217-227.
14.
Bansal T, Jaggi M, Khar RK, Talegaonkar S: Emerging significance of flavonoids as p-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 2009;12:46-78.
15.
Kimura Y, Ito H, Ohnishi R, Hatano T: Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem Toxicol 2010;48:429-435.
16.
Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O: Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 1997;94:2031-2035.
17.
Yasar U, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML, Eliasson E: Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 2001;29:1051-1056.
18.
Kaukonen KM, Olkkola KT, Neuvonen PJ: Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998;53:445-449.
19.
Yasar U, Eliasson E, Forslund-Bergengren C, Tybring G, Gadd M, Sjoqvist F, Dahl ML: The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 2001;57:729-735.
20.
Chen SZ, Pan PP, Shen LB, Xu SS, Dai DP, Geng PW, Cai J, Cai JP, Hu GX: Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro. Int J Clin Pharmacol Ther 2014;52:732-738.
21.
Hu GX, Zhao BH, Chu YH, Zhou HY, Akingbemi BT, Zheng ZQ, Ge RS: Effects of genistein and equol on human and rat testicular 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 activities. Asian J Androl 2010;12:519-526.
22.
Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet 2005;44:797-814.
23.
Lo MW, Goldberg MR, Mccrea JB, Lu H, Furtek CI, Bjornsson TD: Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995;58:641-649.
24.
Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjöqvist F, Eliasson E, Dahl ML: Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002;71:89-98.
25.
Cao J, Zhang Y, Chen W, Zhao X: The relationship between fasting plasma concentrations of selected flavonoids and their ordinary dietary intake. Br J Nutr 2010;103:249-255.
26.
Sun D, Dong L, Guo P, Yan W, Wang C, Zhang Z: Simultaneous determination of four flavonoids and one phenolic acid in rat plasma by LC-MS/MS and its application to a pharmacokinetic study after oral administration of the herba desmodii styracifolii extract. J Chromatogr B Analyt Technol Biomed Life Sci 2013;932:66-73.
27.
Li LP, Wu XD, Chen ZJ, Sun SY, Ye JF, Zeng S, Jiang HD: Interspecies difference of luteolin and apigenin after oral administration of Chrysanthemum morifolium extract and prediction of human pharmacokinetics. Pharmazie 2013;68:195-200.
28.
Xie H, Liang Y, Ito Y, Wang X, Chen R, He J, Li H, Zhang T: Preparative isolation and purification of four flavonoids from Daphne genkwa sieb. Et Zucc. By high-speed countercurrent chromatography. J Liq Chromatogr Relat Technol 2011;34:2360-2372.
29.
Liu XY, Xu T, Li WS, Luo J, Geng PW, Wang L, Xia MM, Chen MC, Yu L, Hu GX: The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int 2013;2013:789184.
30.
Zhan Y, Liang BQ, Gu EM, Hu XX, Lin D, Hu GX, Zheng ZQ: Inhibitory effect of apigenin on pharmacokinetics of venlafaxine in vivo and in vitro. Pharmacology 2015;96:118-123.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.